Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSD0922-FU in Advanced Non-small Cell Lung Cancer
NCT06631989Phase 2Recruiting
- Sponsor
- Wayshine Biopharm
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WSD-0922 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Wayshine Biopharm. Primary endpoints: Overall Response Rate by Independent Review Committee up to 1 year, Safety of WSD0922-FU at 8 months and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
WSD-0922
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06631989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631989.